Onmark United: Group Purchasing for Oncology Practices
Unlock affordable, high-quality cancer care with a GPO community that's built by and for physicians.
Trusted expertise, superior specialty drug savings.
We’re entering a new era of care delivery, and with it comes the challenge of managing the costs of exciting new therapies for a growing patient demand. While any GPO can offer you discounts, Onmark® GPO has the proven expertise and track record you can trust to help your practice maximize the full economics available on your drug purchases.
Onmark’s primary focus is getting our members the best pricing possible on their drug purchases. While our members also have access to tools and services such as inventory management and medically integrated dispensing services, we believe a GPO should focus on getting your specialty practice the best possible price on your drug purchases.
With the Onmark approach, our members have access to:
The Onmark GPO stays ahead of new trends in medicine and works continually with manufacturers to deliver new contracts or expand savings on existing contracts. Our approach often allows us to offer GPO pricing at the time of product launch, as well as additional, performance-based savings opportunities for top specialty products.
Providing the best contract portfolio means working closely with our members to understand their needs and provide beneficial drug savings. Whether you’re an existing or potential customer, contact us today to see what Onmark GPO can do for your practice.
Supercharge your purchasing power by aligning on products of choice with like-minded members. Learn about our two GPO programs designed specifically for independent oncology and retina practices.
Unlock affordable, high-quality cancer care with a GPO community that's built by and for physicians.
A GPO community that’s built by and for retina specialists.
Community specialty practices gain controlled access to specialty drugs through our direct-to-provider wholesale distribution.
This biosimilars master class was developed with Dr. Robert Rifkin and a team of expert clinical specialists to understand biosimilar drugs from the FDA view.
Specialty care requires a special approach—one that’s done your way. Let’s connect, and explore how McKesson can optimize your specialty practice.